Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 2/20 | 0.44 |
| ▸ | RUNX1 | Q01196 | 2/20 | 0.40 |
| ▸ | GPR3 | P46089 | 2/20 | 0.40 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.40 |
| ▸ | TUBB | P07437 | 2/20 | 0.40 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.40 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.40 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.40 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.40 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.40 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.40 |
| ▸ | TUBB8 | Q3ZCM7 | 2/20 | 0.40 |
| ▸ | TUBA3E | Q6PEY2 | 2/20 | 0.40 |
| ▸ | TUBA1A | Q71U36 | 2/20 | 0.40 |
| ▸ | TUBA1C | Q9BQE3 | 2/20 | 0.40 |
| ▸ | TUBB6 | Q9BUF5 | 2/20 | 0.40 |
| ▸ | TUBB2B | Q9BVA1 | 2/20 | 0.40 |
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.40 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29956187 | 1.00 | ENPP2 (0.44) | ENPP2RUNX1GPR3TUBB4ATUBB | |
| SCHEMBL3139123 | 0.89 | GPR3 (0.42) | GPR3NPC1RAB9A | |
| SCHEMBL31522728 | 0.89 | GPR3 (0.37) | ENPP2RUNX1GPR3HCRTR1CRHR1 | |
| SCHEMBL29953466 | 0.86 | CA1 (0.42) | ENPP2TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL29956393 | 0.86 | TUBB4A (0.46) | ENPP2RUNX1GPR3TUBB4ATUBB | |
| SCHEMBL17157371 | 0.86 | CA1 (0.42) | ENPP2TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL320667 | 0.86 | TUBB4A (0.46) | ENPP2RUNX1GPR3TUBB4ATUBB | |
| SCHEMBL22208481 | 0.82 | L3MBTL1 (0.44) | GPR3HCRTR1 | |
| SCHEMBL31697241 | 0.82 | L3MBTL1 (0.44) | GPR3HCRTR1 | |
| SCHEMBL30916838 | 0.81 | CA12 (0.46) | RUNX1GPR3CA1CA2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260022100-A1 | NAV1.8 INHIBITOR | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2026-01-22 | — | — | US | disclosed |
| US-20250333383-A1 | N-OXIDE COMPOUNDS AND USE THEREOF | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2025-10-30 | — | — | US | disclosed |
| EP-4609865-A2 | NLRP3 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2025-09-03 | — | — | EP | disclosed |
| US-20250163068-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2025-05-22 | — | — | US | disclosed |
| EP-4545517-A1 | NAV1.8 INHIBITOR | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2025-04-30 | — | — | EP | disclosed |
| EP-4337652-B1 | NLRP3 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2025-04-09 | — | — | EP | disclosed |
| EP-4514777-A1 | N-OXIDE COMPOUNDS AND USE THEREOF | SK Biopharmaceuticals Co., Ltd. (KR) | 2025-03-05 | — | — | EP | disclosed |
| US-20250034101-A1 | COMPOUND HAVING OXADIAZOLE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2025-01-30 | — | — | US | disclosed |
| US-20240409553-A1 | HETEROCYCLIC NLRP3 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2024-12-12 | — | — | US | disclosed |
| US-12145914-B2 | Compound having oxadiazole and pharmaceutical composition containing the same | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2024-11-19 | — | — | US | disclosed |
| EP-1399428-A1 | 2,5-DIARYLPYRAZINES, 2,5-DIARYLPYRIDINES AND 2,5-DIARYLPYRIMIDINES AS CRF1 RECEPTOR MODULATORS | Neurogen Corporation (US) | 2004-03-24 | — | — | EP | disclosed |
| WO-2004018437-A1 | 5-SUBSTITUTED-2-ARYLPYRAZINES AS MODULATORS OF CRF RECEPTORS | NEUROGEN CORPORATION (US) | 2004-03-04 | — | — | WO | disclosed |
| EP-1392302-A1 | 5-SUBSTITUTED-2-ARYLPYRIDINES AS CRF1 MODULATORS | NEUROGEN CORPORATION (US) | 2004-03-03 | — | — | EP | disclosed |
| US-20030152520-A1 | 5-Substituted-2-arylpyridines | NEUROGEN CORPORATION | 2003-08-14 | — | — | US | disclosed |
| US-20030119844-A1 | 2,5-diarylpyrazines, 2,5-diarylpyridines and 2,5-diarylpyrimidines | NEUROGEN CORPORATION | 2003-06-26 | — | — | US | disclosed |
| US-20030018035-A1 | Substituted arylpyrazines | NEUROGEN CORPORATION | 2003-01-23 | — | — | US | disclosed |
| WO-2002100838-A1 | 2,5-DIARYLPYRAZINES, 2,5-DIARYLPYRIDINES AND 2,5-DIARYLPYRIMIDINES AS CRF1 RECEPTOR MODULATORS | NEUROGEN CORPORATION (US) | 2002-12-19 | — | — | WO | disclosed |
| WO-2002096421-A1 | 5-SUBSTITUTED-2-ARYLPYRIDINES AS CRF1 MODULATORS | NEUROGEN CORPORATION (US) | 2002-12-05 | — | — | WO | disclosed |
| EP-1255740-A2 | SUBSTITUTED ARYLPYRAZINES | NEUROGEN CORPORATION (US) | 2002-11-13 | — | — | EP | disclosed |
| WO-2001060806-A2 | SUBSTITUTED ARYLPYRAZINES | NEUROGEN CORPORATION (US) | 2001-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030119844-A1 | 2,5-diarylpyrazines, 2,5-diarylpyridines and 2,5-diarylpyrimidines | CRHR2, CRHR1, CRH | ENPP2 630/4885RUNX1 1461/4885GPR3 123/4885 |
| US-20250333383-A1 | N-OXIDE COMPOUNDS AND USE THEREOF | SCNN1B, SCN1B, SCN2B | ENPP2 1629/4885RUNX1 2842/4885GPR3 1597/4885 |
| US-20250034101-A1 | COMPOUND HAVING OXADIAZOLE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | OTC, OXA1L, ATP6V1B2 | ENPP2 2771/4885RUNX1 3686/4885GPR3 796/4885 |
| US-20260022100-A1 | NAV1.8 INHIBITOR | SCN8A, SCN1B, SCN1A | ENPP2 3807/4885RUNX1 1521/4885GPR3 500/4885 |
| US-20030152520-A1 | 5-Substituted-2-arylpyridines | HTR5A, CRHR2, HTR2C | ENPP2 2049/4885RUNX1 1770/4885GPR3 116/4885 |
| US-20250163068-A1 | COMPOUNDS AND THEIR METHODS OF USE | SCN1A, SCN3A, SCN1B | ENPP2 384/4885RUNX1 2437/4885GPR3 1830/4885 |
| US-20240409553-A1 | HETEROCYCLIC NLRP3 INHIBITORS | NLRP3, NLRP1, NOD1 | ENPP2 2682/4885RUNX1 3291/4885GPR3 731/4885 |
| US-12145914-B2 | Compound having oxadiazole and pharmaceutical composition containing the same | OTC, OXA1L, ATP6V1B2 | ENPP2 2771/4885RUNX1 3686/4885GPR3 796/4885 |
| US-20030018035-A1 | Substituted arylpyrazines | CRHR1, CRHR2, CRH | ENPP2 483/4885RUNX1 1026/4885GPR3 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.